Single iron infusion more effective for treating iron deficiency anaemia in pregnancy
Image Credit: Karolinska Institutet / AI generated
Scientific Frontline: Extended "At a Glance" Summary: Single-Dose Iron Infusion for Pregnancy Anaemia
The Core Concept: A one-time intravenous infusion of ferric carboxymaltose is a highly effective treatment for iron deficiency anaemia during pregnancy. It rapidly and efficiently restores iron levels compared to traditional daily oral supplements.
Key Distinction/Mechanism: Unlike standard oral iron tablets (ferrous sulphate) that require multiple daily doses and frequently cause gastrointestinal side effects leading to poor compliance, the single-dose intravenous infusion bypasses the digestive system. This ensures full absorption, quicker recovery from anaemia, and a reduction in severe bleeding complications after childbirth.
Major Frameworks/Components:
- Ferric Carboxymaltose: The specific intravenous iron formulation used as the single-dose treatment.
- Ferrous Sulphate Comparison: The traditional multi-dose oral regimen used as the baseline for efficacy and cost comparisons.
- Decision Tree Modeling: The analytical method used by researchers to compare treatment recovery rates, childbirth complications, and overall cost-effectiveness.
- Cost-Utility Analysis: Evaluating the higher upfront cost of the infusion against the long-term health value and reduced complication expenses.
Branch of Science: Obstetrics, Gynaecology, Global Public Health, and Hematology.
Future Application: The treatment is targeted for integration into routine antenatal care, particularly in low-resource countries. Efforts are underway to include it in essential medicines lists (such as in Nigeria) and to negotiate price reductions or health insurance coverage to offset initial costs.
Why It Matters: Iron deficiency anaemia is a major global health concern during pregnancy. Providing a practical, highly effective, and cost-efficient alternative to daily pills significantly improves maternal health outcomes and reduces the risk of life-threatening postpartum complications.
Treating pregnancy-related iron deficiency anemia with a one-time iron infusion provides better health outcomes and greater value than standard iron tablets, according to a new study published in The Lancet Obstetrics, Gynecology & Women’s Health. The findings may help guide healthcare decisions in low-resource settings.
Iron deficiency anemia is a major public health concern, especially during pregnancy. Traditional oral iron tablets are widely used, but many women struggle with side effects or difficulties taking them every day, which limits the treatment's efficacy. In this study, researchers evaluated whether a single-dose intravenous iron treatment, ferric carboxymaltose, could offer a more cost-effective alternative.
The study analyzed data from a large clinical trial involving 1,056 pregnant women aged 15–49 years, all between 5 and 7.5 months pregnant and with hemoglobin levels below 10 g/dL. Half received iron tablets three times a day until delivery, while the other half received a single iron infusion. Using these data, the research team developed a decision tree model to compare the treatments in terms of recovery from anemia, complications such as severe bleeding after childbirth, and overall costs.
A Practical and Cost-Effective Option
“We saw that many women could not benefit fully from oral iron because of side effects or challenges remembering to take the tablets every day,” says Dr. Opeyemi Akinajo, who recently completed her doctoral studies at the Department of Global Public Health. “A single-dose infusion, given once over a short period, helped restore iron levels more quickly and effectively.”
The analysis showed that the infusion led to fewer health problems related to iron deficiency anemia and provided better value for the money, even though the upfront cost was higher. According to the researchers, the findings carry strong policy relevance for countries where resources are limited.
“Our results suggest that a one-time intravenous treatment can be a practical and cost-effective option for managing iron deficiency anemia in pregnancy, particularly in low-resource settings,” says Dr. Akinajo. “Lowering the cost of the infusion would further improve access and help more women benefit from this treatment.”
The research team now aims to explore how iron infusions can be integrated into routine antenatal care. This includes assessing strategies such as price negotiations, inclusion in health insurance schemes, and policy changes. The group is currently collaborating with the Nigerian Federal Ministry of Health to support adding the treatment to the essential medicines list.
Funding: Bill & Melinda Gates Foundation, and the researchers report no conflicts of interest.
Published in journal: The Lancet Obstetrics, Gynaecology, & Women's Health
Authors: Opeyemi Rebecca Akinajo, Prof Kristi Sidney Annerstedt, Maria Teresa Santos, Prof Bosede Bukola Afolabi, and Prof Aduragbemi Banke-Thomas
Source/Credit: Karolinska Institutet | Ann-Sofie Maria Sten
Reference Number: med050426_01